Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Biomerica, Inc. (BMRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.7600-0.2100 (-4.23%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.9700
Open5.0000
Bid4.7300 x 1400
Ask5.0500 x 1800
Day's Range4.7200 - 5.0200
52 Week Range3.3000 - 8.1500
Volume95,832
Avg. Volume2,130,973
Market Cap58.558M
Beta (5Y Monthly)-0.66
PE Ratio (TTM)N/A
EPS (TTM)-0.4700
Earnings DateJan 13, 2022 - Jan 17, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
  • GlobeNewswire

    Biomerica Forms Scientific Advisory Board for Colorectal Cancer Screening

    Chaired by Dr. Brooks Cash, Chief of Gastroenterology and Hepatology at the University of Texas Health Center at HoustonScientific Advisory Board to guide on programs to screen and test patients in US and other countries where colorectal cancer screening is limited due to cost or insufficient laboratory infrastructure Biomerica’s two-minute at home test detects fecal occult (hidden) blood, an early warning sign of colorectal cancerAt home test is now available at Walmart and other retailers IRVI

  • GlobeNewswire

    Biomerica Receives Notice of Allowance from Canadian Patent Office for Patent Covering Irritable Bowel Syndrome (IBS) Food Sensitivity Testing & Treatment

    Studies show that 13-20% of Canadians suffer from IBS at any given time1. The lifetime risk for a Canadian to develop IBS is 30%1. IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today announced that the Canadian Patent Office has issued a notice of allowance for Biomerica’s patent application pertaining to the Company’s InFoods® diagnostic guided therapy platform technology that offers a novel approach in the treatment of patients suffering from Irritable Bowel

  • GlobeNewswire

    Biomerica Launches New Website for Its Aware® Breast Exam Device

    Simple at-home breast exam device provides results within minutesStudies show increase in Breast Exam Sensitivity IRVINE, Calif. , Oct. 29, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that in conjunction with Breast Cancer Awareness month, which takes place each October, it has launched its new website for the Aware® at-home breast self-exam pad. Breast cancer is the most commonly-diagnosed cancer in women. In 2021, an estimated 281,550 new cases of in

Advertisement
Advertisement